(Q38888643)

7 September 2017

1 reference

title

Visceral leishmaniasis: more prevalent and more problematic (English)

1 reference

7 September 2017

main subject

visceral leishmaniasis

1 reference

Baily GG

1

1 reference

7 September 2017

Nandy A

series ordinal

2

1 reference

7 September 2017

publication date

1 November 1994

1 reference

7 September 2017

1 reference

7 September 2017

volume

29

1 reference

7 September 2017

issue

3

1 reference

7 September 2017

page(s)

241-247

1 reference

Epidemiology of visceral leishmaniasis in northeast Brazil

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2991059-6

7 January 2021

Lymphatic leishmaniasis in India

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2991059-6

7 January 2021

Lymphadenopathy in Indian kala-azar

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2991059-6

7 January 2021

Modulation of the cell-mediated immune response in kala-azar and post-kala-azar dermal leishmaniasis in relation to chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2991059-6

7 January 2021

Plasma of Indian kala-azar patients suppresses natural killer cell activity in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2991059-6

7 January 2021

Natural and acquired resistance to Leishmania: cellular activation by Leishmania aethiopica of mononuclear cells from unexposed individuals is through the stimulation of natural killer (NK) cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2991059-6

7 January 2021

Contribution of non-Leishmania-specific immunity to resistance to Leishmania infection in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2991059-6

7 January 2021

Prevalence of Leishmania infection among AIDS patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2991059-6

7 January 2021

Visceral leishmaniasis in patients infected with human immunodeficiency virus. Co-operative Group for the Study of Leishmaniasis in AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2991059-6

7 January 2021

Visceral leishmaniasis in HIV infection and AIDS: clinical features and response to therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2991059-6

7 January 2021

Rectal leishmaniasis in a patient with acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2991059-6

7 January 2021

Leishmaniasis of the tongue treated with liposomal amphotericin B.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2991059-6

7 January 2021

Leishmania braziliensis causing visceral leishmaniasis in a patient with human immunodeficiency virus infection, identified with the aid of the polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2991059-6

7 January 2021

Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2991059-6

7 January 2021

Cardiac effects of sodium stibogluconate

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2991059-6

7 January 2021

Electrocardiographic changes during treatment of leishmaniasis with pentavalent antimony (sodium stibogluconate)

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2991059-6

7 January 2021

Efficacy of amphotericin B in multi-drug resistant kala-azar in children in first decade of life.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2991059-6

7 January 2021

Amphotericin versus pentamidine in antimony-unresponsive kala-azar

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2991059-6

7 January 2021

Liposomal amphotericin B in drug-resistant visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2991059-6

7 January 2021

Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2991059-6

7 January 2021

Aminosidine (paromomycin) in the treatment of leishmaniasis imported into the United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2991059-6

7 January 2021

Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2991059-6

7 January 2021

Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2991059-6

7 January 2021

Comparison of Regimes of Treatment of Antimony-Resistant Kala-Azar Patients: A Randomized Study

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2991059-6

7 January 2021

Ketoconazole in treatment of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2991059-6

7 January 2021

Visceral leishmaniasis unresponsive to antimonial drugs. III. Successful treatment using a combination of sodium stibogluconate plus allopurinol.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2991059-6

7 January 2021

Immunochemotherapy for visceral leishmaniasis: a controlled pilot trial of antimony versus antimony plus interferon-gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2991059-6

7 January 2021

The role of interferon-gamma in the treatment of visceral and diffuse cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2991059-6

7 January 2021

Liposomal amphotericin B for leishmaniasis treatment of AIDS patients unresponsive to antimonium compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2991059-6

7 January 2021

Efficacy of liposomal amphotericin B in the treatment and secondary prophylaxis of visceral leishmaniasis in HIV infected patients: report of two cases

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2894%2991059-6

7 January 2021

10.1016/S0163-4453(94)91059-6

Identifiers

DOI

1 reference

7 September 2017

1 reference